5 things to know before the stock market opens Monday
Here are the most important news items that investors need to start their trading day: 1. Looking for a rebound Stock futures ticked higher Monday after equities tumbled last week. …
Eisai Co Ltd
Leqembi could give Alzheimer’s patients more time, but road to treatment is long
Hannah Yoon | The Washington Post | Getty Images Leqembi, an Alzheimer’s drug from Biogen and Eisai, isn’t a cure for the mind-damaging disease. But the treatment promises to give …
Eisai Biogen Alzheimer’s drug Leqembi shows benefits over three years
The newly FDA approved Alzheimer’s treatment Leqembi is prepared at Abington Neurological Associates in Abington, PA., on Tuesday, November 7, 2023. Hannah Yoon | The Washington Post | Getty Images …
Novo Nordisk GLP-1 liraglutide may slow Alzheimer’s progression
A box of the drug Victoza, made by Novo Nordisk Pharmaceutical, sits on a counter at a pharmacy in Provo, Utah, January 9, 2020. George Frey | Reuters An older, …
Biogen Eisai Alzheimer’s drug Leqembi rejected by European regulator
European drug regulators on Friday rejected the Alzheimer’s treatment Leqembi from Biogen and Eisai, creating another hurdle for the companies as they scramble to boost uptake of the therapy in …
Eli Lilly’s Alzheimer’s drug could help stock join the $1 trillion club
Eli Lilly became the most valuable health-care company in the world on the back of its blockbuster diabetes and obesity drugs. To join the $1 trillion market capitalization club, it …
Biogen (BIIB) earnings Q1 2024
A test tube is seen in front of displayed Biogen logo in this illustration taken on, December 1, 2021. Dado Ruvic | Reuters Biogen on Wednesday reported first-quarter profit that …
Eli Lilly Alzheimer’s drug FDA approval delayed
Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the …
Alzheimerâs drug Leqembi launch, Apple Vision Pro nausea
Good afternoon! The launch of the closely watched Alzheimer’s drug Leqembi is off to a slow start. Still, demand for the treatment from Biogen and its Japanese partner Eisai is rising. …
Biogen (BIIB) earnings Q4 2023
Biogen on Tuesday reported fourth-quarter revenue and profit that shrank from a year ago, as it recorded charges related to dropping its controversial Alzheimer’s drug Aduhelm and as sales slumped …